Stay updated on Long-term Safety of Dupilumab in Pediatric AD Clinical Trial
Sign up to get notified when there's something new on the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page.

Latest updates to the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThere are no significant changes to the study page; only minor visual/textual differences that do not impact the page’s purpose. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check42 days agoChange DetectedSummary of changes: updated operating-status notice and a version bump to v3.2.0, replacing the previous v3.1.0.SummaryDifference2%

- Check49 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

- Check63 days agoChange DetectedThe page's revision tag updated from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed.SummaryDifference0.1%

- Check70 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%

- Check78 days agoChange DetectedThe web page has undergone significant updates, including the addition of specific facility names and locations across various countries, while also removing outdated location references. Notably, the names of cities and regions have been standardized and corrected.SummaryDifference11%

Stay in the know with updates to Long-term Safety of Dupilumab in Pediatric AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page.